Amphastar Pharmaceuticals Inc (OQ:AMPH)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 11570 6th St
RANCHO CUCAMONGA CA 91730
Tel: 1-909-9809484
Website: https://amphastar.com
IR: See website
<
Key People
Mary Ziping Luo
Chairman of the Board, Chief Operating Officer, Chief Scientist
Jack Yongfeng Zhang
President, Chief Executive Officer, Chief Scientific Officer, Director
William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
 
Business Overview
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
Financial Overview
For the fiscal year ended 31 December 2023, Amphastar Pharmaceuticals Inc revenues increased 29% to $644.4M. Net income increased 51% to $137.5M. Revenues reflect Pharmaceutical segment increase of 19% to $579.1M, API segment increase of 13% to $14.1M, United States segment increase of 30% to $635.2M. Net income benefited from Research and development decrease of 48% to $32.6M (expense).
Employees: 1,761 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $2,445M as of Dec 31, 2023
Annual revenue (TTM): $644.40M as of Dec 31, 2023
EBITDA (TTM): $237.72M as of Dec 31, 2023
Net annual income (TTM): $137.55M as of Dec 31, 2023
Free cash flow (TTM): $145.34M as of Dec 31, 2023
Net Debt Last Fiscal Year: $333.21M as of Dec 31, 2023
Shares outstanding: 48,095,862 as of Feb 22, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.